Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is among the best-performing pharma stocks in 2025. AMX0318, a long-acting GLP-1 receptor antagonist, is a development candidate for post-bariatric hypoglycemia and rare diseases. The company expects to complete recruitment for its pivotal Phase 3 LUCIDITY trial of avexitide by Q1 2026, with topline data in Q3 2026.

AMX0318 has shown robust preclinical and chemical properties, potentially supporting long-acting administration. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) believes inhibiting GLP-1 receptor activity is a significant therapeutic approach, with avexitide generating statistically significant data. The company anticipates advancing AMX0318 into IND-enabling studies later this year, targeting an IND by 2027.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) focuses on providing therapies for neurodegenerative diseases and ALS. Its commercial product, Relyvrio (Albrioza in Canada), is available. While AMLX offers investment potential, certain AI stocks may provide greater upside with less risk. Consider exploring AI stock opportunities for potential growth.

For more insightful investment ideas, explore “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy Right Now” on Insider Monkey’s website. No specific disclosures were noted in this article.

Read more at Yahoo Finance: Amylyx Pharmaceuticals (AMLX) Announces the Selection of AMX0318 as Development Candidate for PBH and Other Rare Diseases